Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: A single-center experience

International Archives of Allergy and Immunology

Volumn 157, Issue 4, 2012, Pages 399-405

  Wimazal, Friedrich ^a   Geissler, Philipp ^b   Shnawa, Patrik ^b   Sperr, Wolfgang R ^b,c   Valent, Peter ^b,c  

^a Department of Obstetrics and Gynecology ^*  (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Anaphylaxis; Cladribine; Histamine; Mast cell disease

Indexed keywords

ADRENALIN; CLADRIBINE; CROMOGLYCATE DISODIUM; GLUCOCORTICOID; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST;

ABDOMINAL CRAMP; ADOLESCENT; ADULT; AGED; ANAPHYLAXIS; ARTICLE; BRAIN HYPOXIA; CHILD; DETERIORATION; DIARRHEA; DISABILITY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEADACHE; HOSPITALIZATION; HOT FLUSH; HUMAN; HYMENOPTERA; HYPOTENSION; INSECT STING; MAJOR CLINICAL STUDY; MALE; MAST CELL LEUKEMIA; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RECURRENT DISEASE; RESUSCITATION; SYMPTOM; SYSTEMIC MASTOCYTOSIS; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANAPHYLAXIS; ANTIMETABOLITES; CHILD; CLADRIBINE; FEMALE; HUMANS; MALE; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; PREVALENCE; SEVERITY OF ILLNESS INDEX;

EID: 82055186230     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000329218     Document Type: Article

References (38)

1. Metcalfe DD: Classification and diagnosis of mastocytosis: current status. J Invest Dermatol 1991; 96: 2S-4S.
2. Valent P: Biology, classification and treatment of human mastocytosis. Wien Klin Wochenschr 1996; 108: 385-397. (Pubitemid 26229031)
3. Valent P, Akin C, Sperr WR, Horny HP, Arock M, Lechner K, Bennett JM, Metcalfe DD: Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 2003; 122: 695-717. (Pubitemid 37100296)
4. Akin C, Metcalfe DD: Systemic mastocytosis. Annu Rev Med 2004; 55: 419-432. (Pubitemid 38316735)
5. Horny HP, Valent P: Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 2001; 25: 543-551. (Pubitemid 32506761)
6. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, Metcalfe DD: Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995; 92: 10560-10564.
7. Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, Duffy T, Jacobs P, Tang LH, Modlin I: Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996; 12: 312-314. (Pubitemid 26080092)
8. Féger F, Ribadeau Dumas A, Leriche L, Valent P, Arock M: Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol 2002; 127: 110-114. (Pubitemid 34264196)
9. Bodemer C, Hermine O, Palmérini F, Yang Y, Grandpeix-Guyodo C, Leventhal PS, Hadj-Rabia S, Nasca L, Georgin-Lavialle S, Cohen-Akenine A, Launay JM, Barete S, Feger F, Arock M, Catteau B, Sans B, Stalder JF, Skowron F, Thomas L, Lorette G, Plantin P, Bordigoni P, Lortholary O, de Prost Y, Moussy A, Sobol H, Dubreuil P: Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 2010; 130: 804-815.
10. Escribano L, Orfao A, Diaz-Agustin B, Villarrubia J, Cervero C, Lopez A, Marcos, MA, Bellas C, Fernandez-Canadas S, Cuevas M, Sanchez A, Velasco JL, Navarro JL, Miguel JF: Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 1998; 91: 2731-2736. (Pubitemid 28227522)
11. Valent P, Schernthaner GH, Sperr WR, Fritsch G, Agis H, Willheim M, Bühring HJ, Orfao A, Escribano L: Variable expression of activation-linked surface antigens on human mast cells in health and disease. Immunol Rev 2001; 179: 74-81. (Pubitemid 32171275)
12. Schwartz LB, Sakai K, Bradford TR, Ren S, Zweiman B, Worobec AS, Metcalfe DD: The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest 1995; 96: 2702-2710.
13. Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T: Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987; 316: 1622-1626. (Pubitemid 17082588)
14. Sperr WR, Jordan JH, Fiegl M, Escribano L, Bellas C, Dirnhofer S, Simonitsch-Klupp I, Horny HP, Valent P: Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol 2002; 128: 136-141. (Pubitemid 34639022)
15. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, Marone G, Nunez R, Akin C, Sotlar K, Sperr WR, Wolff K, Brunning RD, Parwaresch RM, Austen KF, Lennert K, Metcalfe DD, Vardiman JW, Bennett JM: Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25: 603-625. (Pubitemid 32506768)
16. Valent P, Horny HP, Li CY, Longley JB, Metcalfe DD, Parwaresch RM, Bennett JM: Mastocytosis; in Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2001, pp 291-302.
17. Valent P, Akin C, Escribano L, Födinger M, Hartmann K, Brockow K, Castells M, Sperr WR, Kluin-Nelemans HC, Hamdy NA, Lortholary O, Robyn J, van Doormaal J, Sotlar K, Hauswirth AW, Arock M, Hermine O, Hellmann A, Triggiani M, Niedoszytko M, Schwartz LB, Orfao A, Horny HP, Metcalfe DD: Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37: 435-453. (Pubitemid 46817344)
18. Horny HP, Metcalfe DD, Bennett JM, Bain BJ, Akin C, Escribano L, Valent P, Bain B: Mastocytosis; in Swerdlow SH, Campo E, Harris NL, Jaffee ES, Pileri SA, Stein H, Thiele J, Varderman JW (eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2008, pp 54-63.
19. Müller UR, Horat W, Wüthrich B, Conroy M, Reisman RE: Anaphylaxis after hymenoptera stings in three patients with urticaria pigmentosa. J Allergy Clin Immunol 1983; 72: 685-689. (Pubitemid 14210903)
20. Kors JW, van Doormaal JJ, de Monchy JG: Anaphylactoid shock following hymenoptera sting as a presenting symptom of systemic mastocytosis. J Intern Med 1993; 233: 255-258. (Pubitemid 23100311)
21. Oude Elberink JN, de Monchy JG, Kors JW, van Doormaal JJ, Dubois AE: Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol 1997; 99: 153-154. (Pubitemid 27074911)
22. Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD: Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol 2002; 81: 677-690. (Pubitemid 36104422)
23. Florian S, Krauth MT, Simonitsch-Klupp I, Sperr WR, Fritsche-Polanz R, Sonneck K, Födinger M, Agis H, Böhm A, Wimazal F, Horny HP, Valent P: Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes. Int Arch Allergy Immunol 2005; 136: 273-280. (Pubitemid 40529199)
24. González de Olano D, Alvarez-Twose I, Esteban-López MI, Sánchez-Muñoz L, de Durana MD, Vega A, García-Montero A, González-Mancebo E, Belver T, Herrero-Gil MD, Fernández-Rivas M, Orfao A, de la Hoz B, Castells MC, Escribano L: Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 2008; 121: 519-526.
25. Niedoszytko M, de Monchy J, van Doormaal JJ, Jassem E, Oude Elberink JN: Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy 2009; 64: 1237-1245.
26. Böhm A, Sonneck K, Gleixner KV, Schuch K, Pickl WF, Blatt K, Peter B, Herrmann H, Schernthaner GH, Pehamberger H, Rabitsch W, Sperr WR, Valent P: In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. Exp Hematol 2010; 38: 744-755.
27. Valent P, Sperr WR, Schwartz LB, Horny HP: Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol 2004; 114: 3-11. (Pubitemid 39005111)
28. Metcalfe DD, Schwartz LB: Assessing anaphylactic risk? Consider mast cell clonality. J Allergy Clin Immunol 2009; 123: 687-688.
29. Akin C: Anaphylaxis and mast cell disease: what is the risk? Curr Allergy Asthma Rep 2010; 10: 34-38.
30. Fricker M, Helbling A, Schwartz L, Müller U: Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. J Allergy Clin Immunol 1997; 100: 11-15. (Pubitemid 27328525)
31. Brockow K, Jofer C, Behrendt H, Ring J: Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008; 63: 226-232.
32. Alvarez-Twose I, González de Olano D, Sánchez-Muñoz L, Matito A, Esteban-López MI, Vega A, Mateo MB, Alonso Díaz de Durana MD, de la Hoz B, Del Pozo Gil MD, Caballero T, Rosado A, Sánchez Matas I, Teodósio C, Jara-Acevedo M, Mollejo M, García-Montero A, Orfao A, Escribano L: Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol 2010; 125: 1269-1278. e2.
33. Arock M, Valent P: Pathogenesis, classification, and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol 2010; 3: 497-516.
34. Tefferi A, Li CY, Butterfield JH, Hoagland HC: Treatment of systemic mast-cell disease with cladribine. N Engl J Med 2001; 344: 307-309. (Pubitemid 32108542)
35. Escribano L, Pérez de Oteyza J, N'ñez R, Orfao A: Cladribine induces immunophenotypical changes in bone marrow mast cells from mastocytosis. Report of a case of mastocytosis associated with a lymphoplasmacytic lymphoma. Leuk Res 2002; 26: 1043-1046. (Pubitemid 35287216)
36. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, van't Wout JW, Verhoef G, Gerrits WB, van Dobbenburgh OA, Pasmans SG, Fijnheer R: Cladribine therapy for systemic mastocytosis. Blood 2003; 102: 4270-4276. (Pubitemid 37494083)
37. Pardanani A, Hoffbrand AV, Butterfield JH, Tefferi A: Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 2004; 28: 127-131. (Pubitemid 37492938)
38. Aichberger KJ, Sperr WR, Gleixner KV, Kretschmer A, Valent P: Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. Eur J Clin Invest 2008; 38: 869-873.